van de Donk, Niels W.C.J.
Amsterdam University Medical Centers · Vrije Universiteit Amsterdam · Amsterdam UMC Location Vrije Universiteit Amsterdam
11 papers on CoChatORCID 0000-0002-7445-2603
Most cited papers
- Verified
Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
Cohen, A. D., Parekh, S., Santomasso, B. D., Gállego Pérez-Larraya, J., van de Donk, N. W. C. J., Arnulf, B., Mateos, M.-V., Lendvai, N., Jackson, C. C., De Braganca, K. C., et al. (2022) · Blood Cancer Journal
CAR-T cell therapy researchMultiple Myeloma Research and Treatments
Cited by 308
- Verified
Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib
Nijhof, I. S., Groen, R. W. J., Noort, W. A., van Kessel, B., de Jong-Korlaar, R., Bakker, J., van Bueren, J. J. L., Parren, P. W. H. I., Lokhorst, H. M., van de Donk, N. W. C. J., et al. (2015) · Clinical Cancer Research
Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research
Cited by 151
- Verified
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence
Katsarou, A., Sjöstrand, M., Naik, J., Mansilla-Soto, J., Kefala, D., Kladis, G., Nianias, A., Ruiter, R., Poels, R., Sarkar, I., et al. (2021) · Science Translational Medicine
CAR-T cell therapy researchImmunotherapy and Immune Responses
Cited by 131
- Verified
Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS)
Landgren, C. O., Chari, A., Cohen, Y. C., Spencer, A., Voorhees, P., Estell, J. A., Sandhu, I., Jenner, M. W., Williams, C., Cavo, M., et al. (2020) · Leukemia
Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research
Cited by 102
- Verified
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
Lonial, S., Popat, R., Hulin, C., Jagannath, S., Oriol, A., Richardson, P. G., Facon, T., Weisel, K., Larsen, J. T., Minnema, M. C., et al. (2022) · The Lancet Haematology
Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors
Cited by 101
- Verified
Preclinical Activity of JNJ-7957, a Novel BCMA×CD3 Bispecific Antibody for the Treatment of Multiple Myeloma, Is Potentiated by Daratumumab
Frerichs, K. A., Broekmans, M. E. C., Marin Soto, J. A., van Kessel, B., Heymans, M. W., Holthof, L. C., Verkleij, C. P. M., Boominathan, R., Vaidya, B., Sendecki, J., et al. (2020) · Clinical Cancer Research
Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research
Cited by 94
- Verified
Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
van de Donk, N. W. C. J., Moreau, P., Garfall, A. L., Bhutani, M., Oriol, A., Nooka, A. K., Martin, T. G., Rosiñol, L., Mateos, M.-V., Bahlis, N. J., et al. (2023) · Journal of Clinical Oncology
Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research
Cited by 71
- Verified
Sequencing multiple myeloma therapies with and after antibody therapies
van de Donk, N. W. C. J. (2020) · Hematology
Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research
Cited by 27
- Verified
Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up
Van De Donk, N. W., Agha, M., Cohen, A. D., Cohen, Y. C., Anguille, S., Kerre, T., Roeloffzen, W. W. H., Schecter, J. M., De Braganca, K. C., Jackson, C. C., et al. (2022) · Blood
CAR-T cell therapy researchMultiple Myeloma Research and Treatments
Cited by 25
- Verified
Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in patients with multiple myeloma (MM) and early relapse after initial therapy: CARTITUDE-2, cohort B.
van de Donk, N. W. C. J., Agha, M. E., Cohen, A. D., Cohen, Y. C., Anguille, S., Kerre, T., Roeloffzen, W., Schecter, J. M., De Braganca, K. C., Varsos, H., et al. (2022) · Journal of Clinical Oncology
CAR-T cell therapy researchMultiple Myeloma Research and Treatments
Cited by 20
- Verified
Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138
van der Schans, J. J., Wang, Z., van Arkel, J., van Schaik, T., Katsarou, A., Ruiter, R., Baardemans, T., Yuan, H., de Bruijn, J., Zweegman, S., et al. (2023) · Clinical Cancer Research
CAR-T cell therapy researchImmunotherapy and Immune Responses
Cited by 17
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free